Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats

Davide Bernareggi, Silvana Canevari, Mariangela Figini

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The concept of "magic bullet" was first proposed by Paul Ehrlich at the beginning of the 20th century, when he conceived the possibility to have a selective compound, linked to a toxin, that would be able to discriminate and kill a disease-causing organism. Research on the immune system and antibodies (Abs) continued, and during the 1960s and 1970s the concept of "cell surface differentiation antigens" and the development of hybridoma technology, for the generation of monoclonal antibodies (mAbs), led to the possibility of distinguishing normal cells from malignant cells. This boosted research on Abs and the development of Ab-based biologic drugs. At present, more than 30 Abs have been approved by the US Food and Drug Administration (FDA) for human therapy in cancer, autoimmunity, and inflammation, and hundreds of new antibody-derived reagents are now in clinical trials.

Original languageEnglish
Title of host publicationAutoantibodies: Third Edition
PublisherElsevier B.V.
Pages83-90
Number of pages8
ISBN (Print)9780444563781
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Monoclonal Antibodies
Antibodies
Magic
Differentiation Antigens
Hybridomas
United States Food and Drug Administration
Therapeutics
Surface Antigens
Autoimmunity
Research
Cell Differentiation
Immune System
Clinical Trials
Inflammation
Technology
Pharmaceutical Preparations
Neoplasms

Keywords

  • Antibody engineering
  • Autoimmunity
  • Cancer
  • Immunotherapy
  • Inflammation
  • Monoclonal antibodies
  • Phage display

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats. / Bernareggi, Davide; Canevari, Silvana; Figini, Mariangela.

Autoantibodies: Third Edition. Elsevier B.V., 2013. p. 83-90.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bernareggi, Davide ; Canevari, Silvana ; Figini, Mariangela. / Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats. Autoantibodies: Third Edition. Elsevier B.V., 2013. pp. 83-90
@inbook{daea42d87fdc400b82d4380d7833cb90,
title = "Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats",
abstract = "The concept of {"}magic bullet{"} was first proposed by Paul Ehrlich at the beginning of the 20th century, when he conceived the possibility to have a selective compound, linked to a toxin, that would be able to discriminate and kill a disease-causing organism. Research on the immune system and antibodies (Abs) continued, and during the 1960s and 1970s the concept of {"}cell surface differentiation antigens{"} and the development of hybridoma technology, for the generation of monoclonal antibodies (mAbs), led to the possibility of distinguishing normal cells from malignant cells. This boosted research on Abs and the development of Ab-based biologic drugs. At present, more than 30 Abs have been approved by the US Food and Drug Administration (FDA) for human therapy in cancer, autoimmunity, and inflammation, and hundreds of new antibody-derived reagents are now in clinical trials.",
keywords = "Antibody engineering, Autoimmunity, Cancer, Immunotherapy, Inflammation, Monoclonal antibodies, Phage display",
author = "Davide Bernareggi and Silvana Canevari and Mariangela Figini",
year = "2013",
month = "12",
doi = "10.1016/B978-0-444-56378-1.00010-1",
language = "English",
isbn = "9780444563781",
pages = "83--90",
booktitle = "Autoantibodies: Third Edition",
publisher = "Elsevier B.V.",

}

TY - CHAP

T1 - Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats

AU - Bernareggi, Davide

AU - Canevari, Silvana

AU - Figini, Mariangela

PY - 2013/12

Y1 - 2013/12

N2 - The concept of "magic bullet" was first proposed by Paul Ehrlich at the beginning of the 20th century, when he conceived the possibility to have a selective compound, linked to a toxin, that would be able to discriminate and kill a disease-causing organism. Research on the immune system and antibodies (Abs) continued, and during the 1960s and 1970s the concept of "cell surface differentiation antigens" and the development of hybridoma technology, for the generation of monoclonal antibodies (mAbs), led to the possibility of distinguishing normal cells from malignant cells. This boosted research on Abs and the development of Ab-based biologic drugs. At present, more than 30 Abs have been approved by the US Food and Drug Administration (FDA) for human therapy in cancer, autoimmunity, and inflammation, and hundreds of new antibody-derived reagents are now in clinical trials.

AB - The concept of "magic bullet" was first proposed by Paul Ehrlich at the beginning of the 20th century, when he conceived the possibility to have a selective compound, linked to a toxin, that would be able to discriminate and kill a disease-causing organism. Research on the immune system and antibodies (Abs) continued, and during the 1960s and 1970s the concept of "cell surface differentiation antigens" and the development of hybridoma technology, for the generation of monoclonal antibodies (mAbs), led to the possibility of distinguishing normal cells from malignant cells. This boosted research on Abs and the development of Ab-based biologic drugs. At present, more than 30 Abs have been approved by the US Food and Drug Administration (FDA) for human therapy in cancer, autoimmunity, and inflammation, and hundreds of new antibody-derived reagents are now in clinical trials.

KW - Antibody engineering

KW - Autoimmunity

KW - Cancer

KW - Immunotherapy

KW - Inflammation

KW - Monoclonal antibodies

KW - Phage display

UR - http://www.scopus.com/inward/record.url?scp=84902057887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902057887&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-56378-1.00010-1

DO - 10.1016/B978-0-444-56378-1.00010-1

M3 - Chapter

SN - 9780444563781

SP - 83

EP - 90

BT - Autoantibodies: Third Edition

PB - Elsevier B.V.

ER -